Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.

Calcipotriol is the safest and most effective for hair regrowth in localized alopecia areata.

Using 2.5 mg/mL triamcinolone acetonide is effective for hair growth in alopecia areata with fewer side effects.

Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.

Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.

New treatments and strategies are needed for Alopecia Areata, focusing on immune response and better trial designs.

A new type of alopecia areata, called the "confetti variant," causes small bald spots that often heal on their own in a few months.

Severe alopecia areata patients have a low chance of spontaneous hair regrowth.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Low vitamin D levels might indicate more severe hair loss in alopecia areata patients.

Mixing calcipotriol with a steroid is almost as effective as using a steroid alone for alopecia areata and has fewer side effects.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

The guideline provides recommendations for managing alopecia areata effectively.

Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.

The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.

Frontal fibrosing alopecia can affect men's beards and leads to permanent hair loss.

Androgenetic alopecia involves genetics, hormones, and can be treated with medications or surgery.

The document concludes that careful evaluation is key to diagnose and treat women with hair loss, with tests for thyroid, iron, and hormones as needed.

The document explains different types of hair loss, their causes, and treatments, and suggests future research areas.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Bimatoprost is promising for treating some types of hair loss but needs more testing for androgenetic alopecia.

Hair loss is often linked to thyroid problems, especially in women and older people, and screening for thyroid issues is advised for those with hair loss.

Alopecia areata causes unpredictable hair loss, and more research is needed to fully understand and treat it effectively.

Alopecia areata affects 1.45% of people in Japan, impacting mood and self-esteem, with many not seeking treatment.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.

Alopecia areata greatly affects people's life quality, mental health, and work life.

Alopecia areata impacts mental well-being more due to perceptions and stigma than disease severity.